ProfileGDS5678 / 1422724_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 8% 8% 8% 8% 8% 8% 9% 8% 8% 8% 8% 8% 8% 8% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.208278
GSM967853U87-EV human glioblastoma xenograft - Control 22.189178
GSM967854U87-EV human glioblastoma xenograft - Control 32.191948
GSM967855U87-EV human glioblastoma xenograft - Control 42.13968
GSM967856U87-EV human glioblastoma xenograft - Control 52.133568
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.244048
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.23519
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.164638
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.157928
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.175198
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.173178
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.155658
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.182098
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.177638